INTRODUCTION
Before a drug can be approved by the US Food and Drug Administration (FDA), it must demonstrate " substantial evidence " of effectiveness for uses claimed in labeling. The Food, Drug, and Cosmetic Act defi nes substantial evidence as " evidence consisting of adequate and well-controlled investigations. " The drug must not only be effective but also be safe under the conditions of use described in labeling.
The regulations do not specify whether evidence of effectiveness must come from an evaluation of actual clinical benefi t (eg, reduction in anginal symptoms, reduction in stroke, improvement in survival) or from an evaluation of a surrogate end point that substitutes for such clinical benefi t, but the end point has to be clinically meaningful.
In regulations written in 21CFR314.500, Subpart H (Code of Federal Regulations) and in the Food and Drug Administration Modernization Act, the agency gained authority to approve drugs for serious or life-threatening disease with no good available therapy on the basis of an effect of a drug on a surrogate " reasonably likely " to predict clinical benefi t, a standard for surrogates that was explicitly lower than that of established surrogates like blood pressure or low-density lipoprotein (LDL) cholesterol.
Sometimes, if certain conditions are met, a change in a biomarker can function as a surrogate end point in the clinical trials that form the basis of approval of a new drug. There are, however, many other important uses of biomarkers in drug development. They can be used to identify subjects who have disease (diagnostic biomarker) or are at greater risk for disease or some consequence of disease (risk stratifi cation biomarker). They can be used to identify a subgroup of subjects likely to respond to a drug. They can also be used in early clinical development to support the mechanistic hypothesis that led to development of the drug or can be used to predict toxicity (eg, predicting the risk of torsades de pointes via QT interval prolongation on a surface electrocardiogram). Such information can help de termine whether to pursue development or to terminate development early. In addition, biomarkers may be used to estimate a dose-response relationship preliminarily and to determine doses of a new drug to carry forward into later clinical studies.
An area of particular interest -one that is the focus of this report -is the use of biomarkers as surrogate end points. The obvious reasons are that reliance on surrogates can decrease the cost of development and make drugs available earlier. This report will not attempt to address the larger issue of the general basis for reliance on a surrogate but will use blood pressure, generally accepted as a surrogate end point both by clinicians and regulators, to illustrate a particular case in which a surrogate is acceptable.
BIOMARKERS AND SURROGATES: DEFINITIONS AND EXAMPLES
Before considering the basis for accepting change in blood pressure as a surrogate end point for clinical benefi t, it is important to defi ne biomarkers and surrogate end points. Biomarker is a much broader term, including everything from binding affi nity, to genotype, to measures that predict clinical outcomes. A National Institutes of Health biomarker working group has defi ned a biomarker as " a characteristic E147 that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. " 1 As the defi nition suggests, there are many types of biomarkers, including biochemical markers, physiologic markers, anatomic markers, histologic markers, and physical markers. Table 1 lists some examples of cardiovascular and renal  biomarkers. A surrogate end point is a change in a biomarker that can substitute for an observed clinically meaningful end point in the evaluation of the effectiveness of a therapeutic agent. Only a small minority of biomarkers (or changes in biomarkers) are established surrogate end points. One defi nition of a surrogate end point is " a laboratory measurement or physical sign that is used in therapeutic trials as a substitute for a clinically meaningful end point that is a direct measure of how a patient feels, functions, or survives and is expected to predict the effect of the therapy. " 2 The effect on the surrogate end point (eg, blood pressure reduction) is not itself of benefi t to the patient. That is, people do not usually feel better immediately when their blood pressure or LDL cholesterol is lowered by drugs. Instead, treatment of the surrogate is of value only if the expected effect on a clinical outcome actually occurs. Table 2 lists examples of surrogate end points that relate to cardiovascular and renal drugs and are accepted by the agency. There are, of course, plausible effects on biomarkers (eg, ventricular premature beat suppression post -myocardial infarction or improved cardiac output in heart failure) that have not proven to predict clinical benefi t. 3 , 4 Effects on biomarkers become established surrogates in various ways. For example, serum creatinine is a direct measure of renal function -what might be called a physiologic or functional measure of the integrity of the kidney. It is not hard to conclude that decreasing the rate of increase in serum creatinine in people with diabetic nephropathy would lead to a decreased rate of renal failure, and the early studies of captopril in type 1 diabetics showed this to be true. Other potential surrogates, such as blood pressure or LDL cholesterol, were controversial because they were not direct measures of stroke or coronary artery disease and because there were doubts as to whether improving them would be beneficial. In the 1930s, Paul Dudley White, one of the founders of the American Heart Association, stated that " hypertension may be an important compensatory mechanism which should not be tampered with, even if it were certain that we could control it, " 5 and such views continued to be heard into the 1960s 6 and 1970s. 7 For surrogates that lack a clear physiologic or functional correlate (eg, creatinine), the process of establishing a biomarker as a surrogate end point has generally involved 3 stages. First, there is biologic plausibility, sometimes intuitive, sometimes supported by animal data or by favorable responses in extreme cases (eg, malignant hypertension). Second, there are epidemiologic or natural history data demonstrating that increases (or decreases) in the putative surrogate are correlated with unfavorable (or favorable) clinical outcomes. The correlation between a putative surrogate and clinical outcomes of interest has been identifi ed by Prentice 8 as 1 of 2 main criteria in establishing a surrogate end point. But while correlation is necessary, it is not suffi cient. As stated by Fleming and DeMets, " a correlate does not a surrogate make, " 9 because the correlation may not refl ect causality. In the case of blood pressure, for example, the epidemiologic studies cannot alone reveal whether blood pressure elevation is the cause of cardiovascular disease or is itself benign and is simply a consequence of some other risk factor that is the cause of cardiovascular disease.
Prentice identifi ed a second main criterion for a surrogate: the putative surrogate should fully capture the effect of treatment on clinical outcomes. In other words, it is important to demonstrate from controlled clinical trials that changes in the putative surrogate resulting from at least 1 type of intervention, and preferably many types, working by different mechanisms, affect clinical outcomes in a predictable manner that is fully accounted for by the effect on the surrogate. This is a very demanding criterion. As will be emphasized later, it must always be appreciated that the pharmacologic effect on the surrogate and ultimately on the outcome of interest is often not the only effect of the drug; there may be other effects that can be adverse (eg, hypokalemia with high-dose diuretics) or favorable (eg, effects on heart failure unrelated to blood pressure effects with some antihypertensives). 
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EPIDEMIOLOGY OF HYPERTENSION
The relationship between blood pressure and cardiovascular mortality and morbidity (eg, heart failure, angina, myocardial infarction, stroke, aortic dissection, renal failure) has been shown to be consistent in multiple observational studies and to be present for sex, age, and race subsets of the population. A meta-analysis of 9 studies published by MacMahon et al documented the association between diastolic blood pressure (DBP) and stroke and coronary heart disease (CHD) in over 400 000 subjects. 10 The study subjects were predominantly North American males (96%) who did not have a history of stroke or myocardial infarction at baseline. The study found that there was a positive, continuous, loglinear relationship between DBP and stroke/CHD events within the range of DBP 70 to 110 mmHg. The relationship between blood pressure and cardiovascular morbidity/ mortality is not sex-specifi c. An analysis of the Framingham study showed that hypertensive women also are at increased risk for major cardiovascular disease outcomes, including cardiac failure, stroke, CHD, and peripheral arterial disease. 11 The relationship between blood pressure and cardiovascular morbidity/mortality is also not limited to any particular race. An analysis of the Multiple Risk Factor Intervention Trial (MRFIT) data that included black males showed a correlation between DBP and death rates from stroke. 12 , 13 Additionally, an analysis of the relationship between blood pressure and CHD mortality in 6 different regions of the world showed that although there were differences in CHD mortality that varied by a factor of 3 across the different regions, the risk of CHD mortality increased with increasing systolic blood pressure in every region. 14 The MRFIT data also showed that the relationship between blood pressure and cardiovascular mortality and morbidity is also present at all ages. 15 The relationship between blood pressure and adverse cardiovascular outcomes is not limited to any particular parameter used to assess blood pressure (systolic and diastolic, systolic alone, or diastolic alone). In particular, while for decades diastolic pressure was used to defi ne hypertension, systolic pressure has proven at least equally predictive of outcomes, and it is clear that the high systolic pressure seen in older people is not benign. 16 , 17
CLINICAL TRIAL DATA ON OUTCOMES
The benefi ts of pharmacologic lowering of blood pressure have been demonstrated in numerous randomized placeboor active-controlled trials of substantial size that used a variety of pharmacologic agents or classes of agents. Regardless of the pharmacologic mechanism by which blood pressure lowering occurs, the most consistent benefi t demonstrated has been reduction of stroke and coronary heart disease. Table 3 provides a list of prospective, randomized, mostly placebo-controlled trials conducted over the last 3 to 4 decades that demonstrate the benefi t of antihypertensive therapy. As shown in the table, a variety of pharmacologic agents have been represented, including diuretics, beta-adrenergic receptor blockers, angiotension converting enzyme (ACE) inhibitors, calcium channel blockers, and angiotensin receptor blockers. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The fact that similar results have emerged from studies that used pharmacologically distinct agents provides strong evidence that it is the effect on blood pressure, not some other property of the drugs, that mediates the benefi cial effects seen.
LIMITATIONS OF SURROGATES
The general limitations of relying on a surrogate end point or a putative surrogate have been described. 9 The possibility that the pharmacologic effect on the surrogate will not affect the desired outcome has been alluded to earlier in this report. As noted, the many different pharmacologic interventions that lead to the same outcome strongly indicate that it is the effect on blood pressure itself that leads to the favorable outcome. That does not mean, however, that all interventions will have the same outcome effect for a given change in blood pressure, because drugs can have additional effects, independent of the effect on the surrogate, and these can infl uence clinical outcomes. This may not be so surprising, as drugs often have unexpected additional effects, either benefi cial or harmful.
As an example, the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study 
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was a randomized, blinded, active-controlled hypertension outcome study that compared the effi cacy of 4 antihypertensive agents (chlorthalidone, lisinopril, amlodipine, and doxazosin) on the primary outcome of CHD mortality and nonfatal myocardial infarction. The agents could not be distinguished for this end point, but doxazosin had a relative risk of congestive heart failure that was 2.04-fold (95% CI → 1.79 -2.32) higher than that of chlorthalidone. 30 This is not an example of a failed surrogate, but it does highlight the fact that drugs can have additional effects on clinical outcomes of interest.
In another example, the Irbesartan Diabetic Nephropathy Trial (IDNT) study 31 showed that in hypertensive patients with type 2 diabetes mellitus, irbesartan reduced the risk of progression to doubling of serum creatinine and onset of end-stage renal disease relative to placebo. The blood pressure lowering with amlodipine, the active comparator in the IDNT study, was similar in magnitude to that of irbesartan. Despite the similar antihypertensive effect, however, amlodipine could not be distinguished from placebo in its effects on progression to doubling of serum creatinine and progression to end-stage renal disease.
There is now great interest in whether some individual agents or antihypertensive regimens yield better outcome results than others. [32] [33] [34] Recent reports from studies such as Losartin Intervention for Endpoint Reduction Trial (LIFE), 29 which have compared the blood pressure -lowering effects of losartan and atenolol in hypertensive patients with left ventricular hypertrophy, have suggested that atenolol has a smaller effect than losartan does on stroke. The issue is still unresolved, however.
Thus, even the use of a well-established surrogate cannot guarantee that there will not be differences in clinical outcomes between treatments with similar effects on the surrogate. Similar issues arise in other cases. For example, there is active discussion of whether the effects of 3 hydroxy-3 methyl glutaryl coenzyme (HMG CoA) reductase inhibitors (statins) on LDL cholesterol fully account for the drugs ' effects on clinical outcomes or whether there are additional effects (eg, antiinfl ammatory effects) that 
SUBPART H APPROVAL
In 1992, the FDA published a fi nal rule 35 that put in place a new mechanism for approval of drugs: Subpart H, the accelerated approval of new drugs for serious or life-threatening illnesses. Accelerated approval allows the agency to base marketing approval on a drug ' s effect on a " surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefi t. " Subpart H approval is limited to diseases that are " serious or life-threatening " and that lack good available therapy. The " reasonably likely " standard is interesting in that it is clearly stated that this is a lower standard than that used for surrogates for full approval (eg, blood pressure, LDL cholesterol), but the " usual " standard is nowhere defi ned in regulations. The rule states that there should be evidence of biologic plausibility and some natural history or epidemiologic evidence demonstrating the association of the surrogate and clinical outcomes. Approval under Subpart H is subject to the requirement that the sponsor conduct postmarketing clinical studies to " verify and describe the drug ' s clinical benefi t and to resolve remaining uncertainty as to the relation of the surrogate endpoint upon which approval was based to clinical benefi t, or the observed clinical benefi t to ultimate clinical outcome. " 35
CONCLUSION
Biomarkers have well-established, valuable roles in drug development, including helping to identify patients at risk for disease, select doses for study, identify patients likely to respond to therapy, and monitor disease activity. In addition, when certain criteria are met, effects on biomarkers can function as surrogate end points that can be studied in wellcontrolled trials and used as a basis for approval. In this report, we have discussed blood pressure as an example of a biomarker that has become a well-established surrogate end point, on the basis of natural history/epidemiologic data and numerous placebo-or active-controlled outcome trials of a variety of agents that correlate reductions in blood pressure with reductions in the risk of cardiovascular events. Blood pressure, as a surrogate end point, is unusual in that many drugs for blood pressure (eg, thiazides, methyldopa, reserpine, hydralazine, guanethidine) were approved before there was an effectiveness requirement (1962) and before there was clinical trial evidence of benefi t from control of blood pressure (1967).
